Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 12Phase 1 9Phase 3 4Phase NA 2Phase 4 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Lymphoma 35Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30Leukemia, Lymphocytic, Chronic, B-Cell 16Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Leukemia 11Lymphoma, B-Cell 10Waldenstrom Macroglobulinemia 8Lymphoma, T-Cell, Cutaneous 8Hodgkin Disease 8Mycosis Fungoides 6Lymphoma, Mantle-Cell 6Neoplasm, Residual 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Extranodal NK-T-Cell 5Febrile Neutropenia 5Burkitt Lymphoma 5Asthma 5Pain 4Neoplasms 4Multiple Myeloma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Sezary Syndrome 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3

Interventions

obinutuzumab 1acalabrutinib 1Rituximab 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Lymphatic Diseases × Lymphoid × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Takeda

Phase 4 Completed
60 enrolled 21 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡